Skip to main content
. Author manuscript; available in PMC: 2020 Feb 24.
Published in final edited form as: Bioorg Med Chem. 2013 Mar 14;21(12):3523–3532. doi: 10.1016/j.bmc.2013.03.001

Figure 2.

Figure 2.

Binding of full-length Vif and Vif CTD to A3G derived peptides–Peptide array screening results: (A) Binding of full length (His)6-Vif and Vif CTD 141–192 to the peptide array. Detection was performed using mouse anti-Vif monoclonal antibody followed by incubation with HRP-conjugated goat anti-mouse secondary antibody and ECL development. For more information please refer to Tables 2 and S1. (B) Schematic representation of A3G peptides that bound full-length Vif (purple boxes) and Vif CTD (red boxes) are indicated above the A3G domains.